Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02576574 · ClinicalTrials.gov registry record · Phase 3
Avelumab in First-line NSCLC (JAVELIN Lung 100)
A Phase 3 study, sponsored by EMD Serono Research & Development Institute.
- Completed
- Registry status
- Phase 3
- Development phase
- 1,214
- Enrollment target
NCT02576574 is a Phase 3 study that has completed, run by EMD Serono Research & Development Institute. The registered enrollment target is 1,214 participants.
The verdict
NCT02576574, a Phase 3 study, has completed, sponsored by EMD Serono Research & Development Institute.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,214 participants
- Enrollment target
Study Summary
The purpose of this study was to demonstrate superiority with regard to Overall Survival (OS) or Progression Free Survival (PFS) of avelumab versus platinum-based doublet, based on an Independent Review Committee assessment, in Non-small cell lung cancer (NSCLC) participants with Programmed death ligand 1+ (PD-L1+) tumors.
Interventions
- DRUG Pemetrexed
- DRUG Paclitaxel
- DRUG Gemcitabine
- DRUG Avelumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,214 participants |
| Start Date | 2015-10-29 |
| Est. Completion | 2024-01-29 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02576574
The ClinicalTrials.gov registry entry for NCT02576574 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 1,214 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is EMD Serono Research & Development Institute, which has 81 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Pemetrexed is the first listed.
NCT02576574 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02576574 about?
NCT02576574 is a clinical study titled "Avelumab in First-line NSCLC (JAVELIN Lung 100)". The purpose of this study was to demonstrate superiority with regard to Overall Survival (OS) or Progression Free Survival (PFS) of avelumab versus platinum-based doublet, based on an Independent Review Committee assessment, in Non-small cell lung cancer (NSCLC) participants with Programmed death li...
What is the current status of trial NCT02576574?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,214 participants. The study started on 2015-10-29. Estimated completion is 2024-01-29.
What interventions are being tested in trial NCT02576574?
The interventions under investigation include: Pemetrexed (DRUG), Paclitaxel (DRUG), Gemcitabine (DRUG), Avelumab (DRUG).
Who is sponsoring clinical trial NCT02576574?
This trial is sponsored by EMD Serono Research & Development Institute, which has 81 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.